September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Matrix therapy agent for the treatment of neurotrophic herpetic corneal ulcer in children
Author Affiliations & Notes
  • Livio Giulio Marco Franco
    Eye Clinic, University of Catania, Catania, Italy
  • Maurizio G Uva
    Eye Clinic, University of Catania, Catania, Italy
  • Michele Reibaldi
    Eye Clinic, University of Catania, Catania, Italy
  • Caterina Gagliano
    Eye Clinic, University of Catania, Catania, Italy
  • Mario Damiano Toro
    Eye Clinic, University of Catania, Catania, Italy
  • Roberta Amato
    Eye Clinic, University of Catania, Catania, Italy
  • Giulia Malaguarnera
    Eye Clinic, University of Catania, Catania, Italy
  • Teresio Avitabile
    Eye Clinic, University of Catania, Catania, Italy
  • Antonio Longo
    Eye Clinic, University of Catania, Catania, Italy
  • Footnotes
    Commercial Relationships   Livio Giulio Marco Franco, None; Maurizio Uva, None; Michele Reibaldi, None; Caterina Gagliano, None; Mario Toro, None; Roberta Amato, None; Giulia Malaguarnera, None; Teresio Avitabile, None; Antonio Longo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5734. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Livio Giulio Marco Franco, Maurizio G Uva, Michele Reibaldi, Caterina Gagliano, Mario Damiano Toro, Roberta Amato, Giulia Malaguarnera, Teresio Avitabile, Antonio Longo; Matrix therapy agent for the treatment of neurotrophic herpetic corneal ulcer in children. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5734.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy of a matrix therapy agent for the treatment of neurotrophic herpetic corneal ulcer in children.

Methods : Six eyes of six children affected by neurotrophic corneal ulcer resistant to treatment were included in the study. All eyes had previous treatment with systemic acyclovir, topical antibiotic ointment (tid), and preservative–free artificial tears. In presence of a resistant ulcer, failing to heal (or to improve) despite at least 1 month of treatment, with corneal anesthesia/hypoestesia, a matrix therapy agent [Poly(Carboxymethylglucose Sulfate), ReGeneraTing Agent, RGTA] was prescribed, with one application in the evening, as the last eye drop, on alternate days. Systemic acyclovir, chloramphenicol/tetracycline ointment (tid), and preservative –free artificial tears were continued. Controls were performed weekly. The area of corneal ulcer, as detected in anterior segment photographs, and measured by Image J software, and the depth of ulcer as detected by anterior segment OCT were evaluated. Corneal sensitivity at baseline was assessed with a Cochet-Bonnet esthesiometer.

Results : Six eyes of six patients (2 m, 4 f, age 5-11 years, median 8 years) received RGTA treatment. At baseline the area of the corneal ulcers ranged from 6 to 18% of the corneal surface (median 11%); in all eyes small neovessels can be seen in the area of ulcer; all patients had a reduced corneal sensitivity in the affected eye (median 2 cm vs. 6 cm in fellow eyes, P=0.001). In all eyes corneal ulcer healed, after 3-7 weeks (median 5 weeks) of treatment. Compared to baseline, a significant reduction of the area of corneal ulcer was seen at week 2 (P=0.018), and at the following time points (P<0.001). Anterior segment OCT showed, after the healing of the ulcer, a progressive thickening of the corneal epithelium, with partial regularization of the corneal surface profile.

Conclusions : Topical treatment with matrix therapy agent RGTA can be useful in treatment of neurotrophic herpetic corneal ulcers in children, improving the healing of the lesion.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×